Clinical trials of the new thrombopoietin receptor agonists in the management of chemotherapy-induced thrombocytopenia are needed to address concerns about the safety and practical efficacy new agents before we accept them as standard therapies.
Mojibade N. Hassan
Advertisement
Articles by Mojibade N. Hassan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
3
Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview
4
Exploring the Future of Bladder-Sparing Regimens in the MIBC Landscape
5